Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 2, 2011, Pages 294-300

  Szabados Nacsa, A ^a   Sipos, P ^a   Martinek, T ^a   Mandity I ^a   Blazso G ^a   Balogh, A ^a   Szabo Revesz P ^a   Aigner, Z ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

DIMEB inclusion complex; DOSY; ESI MS; In vivo examination; Loratadine; PH independent solubility

Indexed keywords

CYCLODEXTRIN DERIVATIVE; DIMETHYL BETA CYCLODEXTRIN; LORATADINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFUSION ORDERED PROTON NUCLEAR MAGNETIC RESONANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG SOLUBILITY; ELECTROSPRAY MASS SPECTROMETRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OSMOLARITY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HYDROGEN-ION CONCENTRATION; LORATADINE; MALE; RATS; RATS, WISTAR; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 79952241735     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.01.024     Document Type: Article

References (24)

1. Linnankoski J., Ranta V.-P., Yliperttula M., Urtti A. Passive oral drug absorption can be predicted more reliably by experimental than computational models-fact or myth. Eur. J. Pharm. Sci. 2008, 34:129-139.
2. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12:413-420.
3. Avdeef A., Kansy M., Bendels S., Tsinman K. Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis. Eur. J. Pharm. Sci. 2008, 33:29-41.
4. Leuner C., Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000, 50:47-60.
5. Khan M.Z., Rausl D., Zanoski R., Zidar S., Mikulcić J.H., Krizmanić L., Eskinja M., Mildner B., Knezević Z. Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation. Biol. Pharm. Bull. 2004, 27:1630-1635.
6. Estelle F., Simons R. Comparative pharmacology of H1 antihistamines: clinical relevance. Am. J. Med. 2002, 113:38-46.
7. Omar L., El-Barghouthi M.I., Masoud N.A., Abdoh A.A., Al Omari M.M., Zughul M.B., Badwan A.A. Inclusion complexation of loratadine with natural and modified cyclodextrins: phase solubility and thermodynamic studies. J. Solution Chem. 2007, 36:605-616.
8. ter Laak A.M., Tsai R.S., Donné-Op den Kelder G.M., Carrupt P.-A., Testa B., Timmerman H. Lipophilicity and hydrogen-bonding capacity of H1-antihistaminic agents in relation to their central sedative side-effects. Eur. J. Pharm. Sci. 1994, 2:373-384.
9. Bhattachar S.N., Deschenes L.A., Wesley J.A. Solubility: it's not just for physical chemists. Drug Discovery Today 2006, 11:1012-1018.
10. Caliaro G.A., Herbots C.A. Determination of pKa values of basic new drug substances by CE. J. Pharm. Biomed. Anal. 2001, 26:427-434.
11. Nacsa Á., Berkesi O., Szabó-Révész P., Aigner Z. Achievement of pH-independence of poorly-soluble, ionizable loratadine by inclusion complex formation with dimethyl-β-cyclodextrin. J. Incl. Phenom. Macrocycl. Chem. 2009, 64:249-254.
12. Hassan H.A., Al-Marzouqi A.H., Jobe B., Hamza A.A., Ramadan G.A. Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide. J. Pharm. Biomed. Anal. 2007, 45:243-250.
13. Nacsa Á., Ambrus R., Berkesi O., Szabó-Révész P., Aigner Z. Water-soluble loratadine inclusion complex: analytical control of the preparation by microwave irradiation. J. Pharm. Biomed. Anal. 2008, 48:1020-1023.
14. Dotsikas Y., Loukas Y.L. Efficient determination and evaluation of model cyclodextrin complex binding constants by electrospray mass spectrometry. J. Am. Soc. Mass Spectrom. 2003, 14:1123-1129.
15. Antalek B. Using pulsed gradient spin echo NMR for chemical mixture analysis: how to obtain optimum results. Concepts Magn. Reson. 2002, 14:225-258.
16. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998, 15:11-22.
17. Blazsó G., Gábor M. Anti-oedematous action of some H1-receptor antagonists. Agents Actions 1994, 42:13-18.
18. Blazsó G., Gábor M. Evaluation of the anti-oedematous effects of some H1-receptor antagonists and methysergide in rats. Pharmacol. Res. 1997, 35:65-71.
19. Nuutinen J.M.J., Irico A., Vincenti M., Dalcanale E., Pakarinen J.M.H., Vainiotalo P. Gas-phase ion-molecule reactions between a series of protonated diastereomeric cavitands and neutral amines studied by ESI-FTICRMS: gas-phase inclusion complex formation. J. Am. Chem. Soc. 2000, 122:10090-10100.
20. Béni S., Szakács Z., Csernák O., Barczac L., Noszál B. Cyclodextrin/imatinib complexation: binding mode and charge dependent stabilities. Eur. J. Pharm. Sci. 2007, 30:167-174.
21. Djedaïni-Pilard F., Nevers M.C., Weisse S., Grassi J., Perly B., Créminon C., et al. A sensitive and specific enzyme immunoassay for the detection of methyl ether derivatives of cyclomaltoheptaose. Carbohydr. Res. 2003, 338:2091-2099.
22. Jullian C., Miranda S., Zapata-Torres G., Mendizábal F., Olea-Azar C. Studies of inclusion complexes of natural and modified cyclodextrin with (+)catechin by NMR and molecular modelling. Bioorg. Med. Chem. 2007, 15:3217-3224.
23. Nally R., Isaacs L. Toward supramolecular polymers incorporating double cavity cucurbituril hosts. Tetrahedron 2009, 65:7249-7258.
24. Arima H., Yunomae K., Hirayama F., Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-b-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 2001, 297:547-555.